Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections.

abstract：:Quinupristin-dalfopristin (RP 59500) is an injectable streptogramin antibiotic. It possesses a wide spectrum of activity against Gram-positive bacteria including methicillin-resistant staphylococci, glycopeptide-resistant. Enterococcus faecium and penicillin-resistant pneumococci. Quinupristin-dalfopristin has activit...

journal_title：Drugs

authors： Bryson HM,Spencer CM

更新日期：1996-09-01 00:00:00

abstract：:Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors...

journal_title：Drugs

authors： Van Hoecke H,Vandenbulcke L,Van Cauwenberge P

更新日期：2007-01-01 00:00:00

abstract：:The effects of enalapril on clinical well-being, treadmill exercise performance, haemodynamic measurements, hormone levels, and plasma biochemistry in patients with moderate heart failure, were assessed in a 12-week placebo-controlled, double-blind study. Maintenance frusemide and digoxin treatment was continued throu...

journal_title：Drugs

authors： Webster MW,Fitzpatrick MA,Hamilton EJ,Nicholls MG,Ikram H,Espiner EA,Wells JE

更新日期：1985-01-01 00:00:00

abstract：:During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

journal_title：Drugs

authors： Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

更新日期：1998-01-01 00:00:00

abstract：:Valsartan/hydrochlorothiazide is a fixed-dose (valsartan 80, 160 or 320mg plus hydrochlorothiazide 12.5 or 25mg) angiotensin II receptor blocker/diuretic drug combination indicated for the treatment of patients with essential hypertension not adequately controlled by monotherapy.There is ample evidence that valsartan/...

journal_title：Drugs

authors： Wagstaff AJ

更新日期：2006-01-01 00:00:00

abstract：:Preclinical studies indicate that angiogenic growth factors can stimulate the development of collateral arteries in animal models of peripheral or myocardial ischaemia, a concept termed 'therapeutic angiogenesis'. The goal of this review is to provide a brief overview of the advantages and disadvantages of gene versus...

journal_title：Drugs

authors： Amant C,Berthou L,Walsh K

更新日期：1999-01-01 00:00:00

abstract：:The rapid spread of human immunodeficiency virus (HIV) infections and the grim outcome of these infections have focused interest on the possibilities for medical intervention. The end-stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated i...

journal_title：Drugs

authors： Sandström EG,Kaplan JC

更新日期：1987-09-01 00:00:00

abstract：:Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...

journal_title：Drugs

authors： Keating GM,Curran MP

更新日期：2003-01-01 00:00:00

abstract：:Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an e...

journal_title：Drugs

authors： Yang LP

更新日期：2011-10-22 00:00:00

abstract：:Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...

journal_title：Drugs

authors： Blanton HL,Brelsfoard J,DeTurk N,Pruitt K,Narasimhan M,Morgan DJ,Guindon J

更新日期：2019-06-01 00:00:00

abstract：:Tipranavir is a non-peptidic HIV-1 protease inhibitor. It binds strongly and selectively, has a favourable resistance profile, and is administered orally twice daily with a subtherapeutic dosage of ritonavir in a 'boosted' regimen (TPV/r) in order to increase its bioavailability. Analysis of clinical isolates from tre...

journal_title：Drugs

authors： Croom KF,Keam SJ

更新日期：2005-01-01 00:00:00

abstract：:During the reproductive period, women generally have lower low-density lipoprotein (LDL) cholesterol and higher high-density lipoprotein cholesterol than age- and diet-matched men. However, these possibly antiatherogenic characteristics of lipoproteins are changed to a potentially atherogenic profile after menopause. ...

journal_title：Drugs

authors： Moghadasian MH

更新日期：2002-01-01 00:00:00

abstract：:This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...

journal_title：Drugs

authors： Elshoff JP,Cawello W,Andreas JO,Mathy FX,Braun M

更新日期：2015-04-01 00:00:00

abstract：:Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

journal_title：Drugs

authors： Berk M,Segal J,Janet L,Vorster M

更新日期：2001-01-01 00:00:00

abstract：:Bruton's tyrosine kinase (BTK) is crucial in B-cell development and survival. The role of BTK as a downstream kinase in the B-cell receptor (BCR) signaling pathway is well described. As a key player in the pathogenesis of B-cell malignancies, targeting of dysregulated BCR signaling has been explored by development of ...

journal_title：Drugs

authors： da Cunha-Bang C,Niemann CU

更新日期：2018-11-01 00:00:00

abstract：:The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Preclinical data in cell lines, patient samples and disease models have bro...

journal_title：Drugs

authors： Seiler T,Hutter G,Dreyling M

更新日期：2016-04-01 00:00:00

abstract：:Suvorexant (Belsomra(®)), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia. Variations in the levels of the neuropeptides orexin A and orexin B have been linked to circadian rhythms and wakefulness. Orexin-producing neuro...

journal_title：Drugs

authors： Yang LP

更新日期：2014-10-01 00:00:00

abstract：:Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less within-patient day-...

journal_title：Drugs

authors： Keating GM

更新日期：2013-05-01 00:00:00

abstract：:In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

journal_title：Drugs

authors： Dhillon S

更新日期：2020-06-01 00:00:00

abstract：:Everolimus is an immunosuppressant that blocks growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Oral everolimus 0.75 or 1.5mg twice daily significantly reduced the incidence of the primary composite endpoint, efficacy failure 6 months after transplantation, compared with azathioprine...

journal_title：Drugs

authors： Chapman TM,Perry CM

更新日期：2004-01-01 00:00:00

abstract：:Budesonide is a glucocorticoid with high topical activity, but low systemic bio-availability which results in reduced systemic effects in comparison with other glucocorticoids. To date, it has been evaluated for use in patients with inflammatory bowel disease when administered either orally as a controlled ileal relea...

journal_title：Drugs

authors： Spencer CM,McTavish D

更新日期：1995-11-01 00:00:00

abstract：:Bronchial asthma is an inflammatory disease. The characteristic pathological features of epithelial cell loss, goblet cell hyperplasia, increased deposition of collagen beneath the basement membrane, mast cell degranulation, and inflammatory cell infiltration of the mucosa are not limited to fatal asthma. Similar infl...

journal_title：Drugs

authors： Beasley R,Roche W,Holgate ST

更新日期：1989-01-01 00:00:00

abstract：:The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure. Flecainide acetate, a class Ic antiarrhythmic agent, was given intravenously to 9 patients with congestive heart failure and frequent ventricular arrhythmias with nonsustained v...

journal_title：Drugs

authors： Dunselman PH,Kingma JH,van Wijk LM,Dijk A,Wesseling H,Lie KI

更新日期：1985-01-01 00:00:00

abstract：:Eltrombopag (Revolade(®)) is an orally bioavailable, low molecular weight, synthetic nonpeptide thrombopoietin receptor agonist, which selectively binds to the transmembrane and juxtamembrane domains of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells, resulting...

journal_title：Drugs

authors： Garnock-Jones KP

更新日期：2011-07-09 00:00:00

abstract：:Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis, while maintaining low...

journal_title：Drugs

authors： Cheer SM,Waugh J,Noble S

更新日期：2003-01-01 00:00:00

abstract：:Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII ...

journal_title：Drugs

authors： Paik J,Deeks ED

更新日期：2019-07-01 00:00:00

abstract：:In a study of the effects of various NSAIDs on renal function in the elderly, indomethacin, tiaprofenic acid and sulindac were administered to patients ranging in age from 54 to 97 years for a period of 3 months. Indomethacin sustained release (25 mg tid) was administered to 66 patients, tiaprofenic acid (200 mg tid) ...

journal_title：Drugs

authors： Ishioka T

更新日期：1988-01-01 00:00:00

abstract：:Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...

journal_title：Drugs

authors： Kumana CR,Yuen KY

更新日期：1994-06-01 00:00:00

abstract：:Chronic pancreatitis is a clinical entity that results from the progressive inflammation and irreversible fibrosis of the pancreas resulting from the cumulative injury sustained by the pancreas over time. It is an illness with variable presentations that can severely impact quality of life, while its long-term complic...

journal_title：Drugs

authors： Kichler A,Jang S

更新日期：2020-08-01 00:00:00

abstract：:An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

journal_title：Drugs

authors： Bigger JT Jr,Leahey EB Jr

更新日期：1982-09-01 00:00:00